Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
The ICR welcomes London Growth Plan
The Institute of Cancer Research, London, is delighted to welcome the new London Growth Plan, launched by Mayor of London Sadiq Khan, which places life sciences at the forefront of an ambitious strategy to boost the capital’s economic growth.
New research might make an ‘undruggable’ target druggable – leading to new cancer drugs
Drug discovery researchers have made significant progress towards targeting a protein that is seen as a promising anticancer target but has, until now, been considered undruggable.